[1]
Krysiak, R.; Okopień, B. Hyperprolactinemia unrelated to prolactinoma. Wiad. Lek., 2014, 67(2 Pt 1), 101-111.
[2]
Ben-Jonathan, N.; Hugo, E.R.; Brandebourg, T.D.; LaPensee, C.R. Focus on prolactin as a metabolic hormone. Trends Endocrinol. Metab., 2006, 17(3), 110-116.
[3]
Donato, J., Jr; Frazão, R. Interactions between prolactin and kisspeptin to control reproduction. Arch. Endocrinol. Metab., 2016, 60(6), 587-595.
[4]
Schmid, C.; Goede, D.L.; Hauser, R.S.; Brändle, M. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med. Wkly., 2006, 136(15-16), 254-258.
[5]
Brown, R.S.; Kokay, I.C.; Herbison, A.E.; Grattan, D.R. Distribution of prolactin-responsive neurons in the mouse forebrain. J. Comp. Neurol., 2010, 518(1), 92-102.
[6]
Pala, N.A.; Laway, B.A.; Misgar, R.A.; Shah, Z.A.; Gojwari, T.A.; Dar, T.A. Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline. Indian J. Endocrinol. Metab., 2016, 20(2), 177-181.
[7]
Shibli-Rahhal, A.; Schlechte, J. The effects of hyperprolactinemia on bone and fat. Pituitary, 2009, 12(2), 96-104.
[8]
Doknic, M.; Pekic, S.; Zarkovic, M.; Medic-Stojanoska, M.; Dieguez, C.; Casanueva, F.; Popovic, V. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur. J. Endocrinol., 2002, 147(1), 77-84.
[9]
Galluzzi, F.; Salti, R.; Stagi, S.; La Cauza, F.; Chiarelli, F. Reversible weight gain and prolactin levels--long-term follow-up in childhood. J. Pediatr. Endocrinol. Metab., 2005, 18(9), 921-924.
[10]
LaPensee, C.R.; Horseman, N.D.; Tso, P.; Brandebourg, T.D.; Hugo, E.R.; Ben-Jonathan, N. The prolactin-deficient mouse has an unaltered metabolic phenotype. Endocrinology, 2006, 147(10), 4638-4645.
[11]
dos Santos Silva, C.M.; Barbosa, F.R.; Lima, G.A.; Warszawski, L.; Fontes, R.; Domingues, R.C.; Gadelha, M.R. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring), 2011, 19(4), 800-805.
[12]
Amato, M.C.; Giordano, C.; Galia, M.; Criscimanna, A.; Vitabile, S.; Midiri, M.; Galluzzo, A. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care, 2010, 33(4), 920-922.
[13]
Ludlam, W. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. Yearbook of Endocrinology, 2011, 2011, 310-311.
[14]
Krysiak, R.; Okopien, B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin. Pharmacol. Toxicol., 2015, 116(3), 251-256.
[15]
Krysiak, R.; Okopien, B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin. Pharmacol. Toxicol., 2015, 116(3), 251-256.
[16]
Ciresi, A.; Amato, M.C.; Guarnotta, V.; Lo Castro, F.; Giordano, C. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin. Endocrinol. (Oxf.), 2013, 79(6), 845-852.
[17]
Soran, H.; Wilding, J.; MacFarlane, I. Body weight and prolactinoma: a retrospective study. Int. J. Obes. Relat. Metab. Disord., 2004, 28(1), 183-183.
[18]
Atadzhanov, M. Dopamine D2 receptor and obesity. Lancet, 2001, 357(9271), 1883.
[19]
Naliato, E.C.O.; Violante, A.H.D.; Caldas, D.; Lamounier Filho, A.; Loureiro, C.R.; Fontes, R.; Schrank, Y.; Souza, R.G.; Costa, P.L.M.; Colao, A. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin. Endocrinol. (Oxf.), 2007, 67(6), 845-852.
[20]
Nagaishi, V.S.; Cardinali, L.I.; Zampieri, T.T.; Furigo, I.C.; Metzger, M.; Donato, J., Jr Possible crosstalk between leptin and prolactin during pregnancy. Neuroscience, 2014, 259, 71-83.
[21]
Gualillo, O.; Lago, F.; García, M.; Menéndez, C.; Señarís, R.; Casanueva, F.F.; Diéguez, C. Prolactin stimulates leptin secretion by rat white adipose tissue. Endocrinology, 1999, 140(11), 5149-5153.
[22]
Baptista, T.; Lacruz, A.; de Mendoza, S.; Mendoza Guillén, J.M.; Silvera, R.; Angeles, F.; Mendoza, M.T.; Hernández, L. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry, 2000, 33(3), 81-88.
[23]
Nilsson, L.; Binart, N.; Bohlooly-Y, M.; Bramnert, M.; Egecioglu, E.; Kindblom, J.; Kelly, P.A.; Kopchick, J.J.; Ormandy, C.J.; Ling, C.; Billig, H. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem. Biophys. Res. Commun., 2005, 331(4), 1120-1126.
[24]
Grattan, D.R.; Kokay, I.C. Prolactin: a pleiotropic neuroendocrine hormone. J. Neuroendocrinol., 2008, 20(6), 752-763.
[25]
Schmid, C.; Goede, D.L.; Hauser, R.S.; Brändle, M. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med. Wkly., 2006, 136(15-16), 254-258.
[26]
Gibson, C.D.; Karmally, W.; McMahon, D.J.; Wardlaw, S.L.; Korner, J. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obes. Metab., 2012, 14(4), 335-340.
[27]
Saadat, N.; Esmaily, H.; Abbasinazari, M.; Tohidi, M.; Salamzadeh, J.; Hadaegh, F.; Tolabi, M.; Kalantar-Hormozi, M.; Dibaj, M. Does twice-weekly cabergoline improve anthropometrical and biochemical profiles in prediabetes? A randomized double-blind clinical trial pilot study. Iran. J. Pharm. Res., 2015, 14(Suppl.), 77-86.
[28]
Berinder, K.; Nyström, T.; Höybye, C.; Hall, K.; Hulting, A-L. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary, 2011, 14(3), 199-207.
[29]
Kamath, V.; Jones, C.N.; Yip, J.C.; Varasteh, B.B.; Cincotta, A.H.; Reaven, G.M.; Chen, Y-D.I. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care, 1997, 20(11), 1697-1701.
[30]
Meier, A.H.; Cincotta, A.H.; Lovell, W.C. Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia, 1992, 48(3), 248-253.
[31]
Via, M.A.; Chandra, H.; Araki, T.; Potenza, M.V.; Skamagas, M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diabetes Metab. Syndr. Obes., 2010, 3, 43-48.
[32]
Perić, B.; Kruljac, I.; Šundalić, S.; Pećina, H.I.; Jović, A.; Štefanović, M.; Butorac, D.; Vrkljan, M. Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link? Endocr. Res., 2016, 41(3), 200-206.
[33]
Hattori, N. Macroprolactinemia: a new cause of hyperprolactinemia. J. Pharmacol. Sci., 2003, 92(3), 171-177.
[34]
Vilar, L.; Moura, E.; Canadas, V.; Gusmão, A.; Campos, R.; Leal, E.; Teixeira, L.; Santos, V.; Gomes, B.; Lima, M.; Paiva, R.; Albuquerque, J.L.; Egito, C.S.; Botelho, C.A.; Azevedo, M.; Casulari, L.A.; Naves, L.A. [Prevalence of macroprolactinemia among 115 patients with hyperprolactinemia]. Arq. Bras. Endocrinol. Metabol, 2007, 51(1), 86-91.
[35]
Kasum, M.; Oreskovic, S.; Zec, I.; Jezek, D.; Tomic, V.; Gall, V.; Adzic, G. Macroprolactinemia: new insights in hyperprolactinemia. Biochem. Med. (Zagreb), 2012, 22(2), 171-179.
[36]
Guerra, E.; Rubino, M.; Di Sarno, A.; Vuolo, L.; Contaldi, P.; Scarano, E. Evaluation of bone mass and fracture in patients with prolactinoma. Endocrine Abstracts, 2012, 29, 1484.
[37]
Aboelnaga, M.M.; Abdullah, N.; El Shaer, M. 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma. Endocr. Metab. Immune Disord. Drug Targets, 2017, 17(3), 219-225.
[38]
Halupczok-Żyła, J.; Jawiarczyk-Przybyłowska, A.; Bolanowski, M. Patients with active acromegaly are at high risk of 25(OH)D deficiency. Front. Endocrinol. (Lausanne), 2015, 6, 89.
[39]
Bonadonna, S.; Mazziotti, G.; Nuzzo, M.; Bianchi, A.; Fusco, A.; De Marinis, L.; Giustina, A. Increased prevalence of radiological spinal deformities in active acromegaly: Aa cross-sectional study in postmenopausal women. J. Bone Miner. Res., 2005, 20(10), 1837-1844.
[40]
Krysiak, R.; Kowalska, B.; Szkróbka, W.; Okopień, B. The association between macroprolactin levels and vitamin D status in premenopausal women with macroprolactinemia: a pilot study. Exp. Clin. Endocrinol. Diabetes, 2015, 123(8), 446-450.
[41]
Jang, H.B.; Lee, H-J.; Park, J.Y.; Kang, J-H.; Song, J. Association between serum vitamin d and metabolic risk factors in korean schoolgirls. Osong Public Health Res. Perspect., 2013, 4(4), 179-186.
[42]
Vanlint, S. Vitamin D and obesity. Nutrients, 2013, 5(3), 949-956.
[43]
Rock, C.L.; Emond, J.A.; Flatt, S.W.; Heath, D.D.; Karanja, N.; Pakiz, B.; Sherwood, N.E.; Thomson, C.A. Weight loss is associated with increased serum 25-hydroxyvitamin D in overweight or obese women. Obesity (Silver Spring), 2012, 20(11), 2296-2301.
[44]
Abrahamian, H.; Kautzky-Willer, A. Sexuality in overweight and obesity. Wien. Med. Wochenschr., 2016, 166(3-4), 121-128.
24
2